The filing also disclosed that on January 6, 2025, Howe acquired 1,250 shares of common stock through the vesting of restricted stock units. These transactions reflect Howe’s ongoing management of her equity holdings in the biopharmaceutical company, which focuses on developing treatments for rare liver diseases. Following these transactions, Howe now holds 2,926 shares of Mirum Pharmaceuticals (NASDAQ:MIRM). InvestingPro analysis reveals the company maintains strong financial health with liquid assets exceeding short-term obligations and a healthy current ratio of 3.34. Subscribers to InvestingPro can access additional insights, including 7 more ProTips and a comprehensive Pro Research Report covering this rapidly growing pharmaceutical company. InvestingPro analysis reveals the company maintains strong financial health with liquid assets exceeding short-term obligations and a healthy current ratio of 3.34. Subscribers to InvestingPro can access additional insights, including 7 more ProTips and a comprehensive Pro Research Report covering this rapidly growing pharmaceutical company.
The filing also disclosed that on January 6, 2025, Howe acquired 1,250 shares of common stock through the vesting of restricted stock units. These transactions reflect Howe’s ongoing management of her equity holdings in the biopharmaceutical company, which focuses on developing treatments for rare liver diseases. Following these transactions, Howe now holds 2,926 shares of Mirum Pharmaceuticals.
In other recent news, Mirum Pharmaceuticals reported robust sales growth, driven by the strong performance of its drug LIVMARLI. The company’s third-quarter net sales rose by 25%, reaching $59.1 million, a significant increase from the same period in the previous year. Following these impressive results, Mirum revised its 2024 global net product sales guidance, now projecting a range of $330 million to $335 million, reflecting an 86% annual growth to the midpoint. The firm H.C. Wainwright reaffirmed a Buy rating on Mirum, noting the promising start for LIVMARLI in treating progressive familial intrahepatic cholestasis (PFIC).
Mirum’s Q3 2024 results also showed an 89% rise in net product sales, primarily driven by LIVMARLI. Despite a net loss for the quarter, the company’s cash reserves remain strong, enabling continued investment in its pipeline, including a new treatment candidate for Fragile X syndrome. Additionally, Mirum acquired MRM-3379 for Fragile X syndrome treatment, emphasizing their strategic focus on rare genetic diseases.
The company also received a breakthrough therapy designation for Volixibat for cholestatic pruritus in PBC patients, and its CHENODAL and CTX NDA are now under priority review. These recent developments, coupled with the strong demand for their products, particularly LIVMARLI, have led to increased revenue guidance, indicating potential for continued growth in the rare disease sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.